Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).
Claire Harrison, MD
Advertisement
Articles by Claire Harrison, MD
Claire Harrison, MD, FRCP, FRCPath, discusses current unmet needs in myelofibrosis.
Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.
Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.
Advertisement
Latest Updated Articles
Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With MyelofibrosisPublished: December 6th 2015 | Updated:
Dr. Harrison on the Current State of Treatment in MyelofibrosisPublished: December 1st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5